Aurinia Raises 2026 Revenue Outlook To $325 Million-$330 Million As Lupus Drug Sales Climb

Third-quarter LUPKYNIS sales rose 12%, and nine-month cash from operations reached $131.5 million.

Share
Aurinia Raises 2026 Revenue Outlook To $325 Million-$330 Million As Lupus Drug Sales Climb

Aurinia Pharmaceuticals, which develops therapies for autoimmune diseases, raised its 2026 total revenue forecast to a range of $325 million to $330 million on Friday, after third-quarter revenue grew 14% to $83.7 million. The earlier range was $315 million to $325 million.

Sales up, profit flat on taxes

Net product sales of LUPKYNIS, Aurinia's oral lupus nephritis therapy, were $79.4 million in the third quarter, up 12% from $70.6 million a year earlier. License, collaboration and royalty revenue rose 54% to $4.3 million from $2.8 million. For the first nine months, total revenue was $244.6 million, up 19%.

Net income was $31.7 million, flat against $31.6 million, or $0.23 per diluted share both years. Pre-tax income climbed 21% to $38.7 million, but income tax expense rose to $7.0 million from $0.4 million.

Research and development spending was $16.6 million in the quarter, up from $8.4 million a year earlier. For nine months, net income rose 35% to $103.5 million, or $0.76 per diluted share.

Guidance narrows on product sales

Aurinia tightened its net product sales outlook to $310 million to $315 million, from $305 million to $315 million. The lifted floor leaves the top of the range unchanged.

The company sells LUPKYNIS in the United States through its own sales team. Its partner Otsuka Pharmaceutical markets the drug in Japan, the European Union, the United Kingdom and Switzerland. Net product sales were $271.3 million in 2025, according to the company's annual report.

Cash pile and buybacks

Cash flow from operations was $46.4 million in the third quarter and $131.5 million for the first nine months, up 46% from $90.0 million a year earlier. Cash, equivalents, restricted cash and investments stood at $486.9 million on September 30, against $398.0 million at the end of 2025.

Over the nine months, Aurinia spent $74.9 million repurchasing 5.0 million of its common shares, partly offset by $35.9 million from share issuance for equity awards, net of tax withholding.

A new combination study

Aurinia has started PRESERVE, a Phase 4 study testing LUPKYNIS alongside belimumab, obinutuzumab or anifrolumab in lupus nephritis. It plans to enroll about 150 patients at about 50 US sites, with complete renal response at six months as the main goal.

The company has also begun clinical development of aritinercept, a dual inhibitor of BAFF and APRIL, in four potential indications.

PRESERVE will measure the share of patients reaching complete renal response at six months.

Sources